Cytokinetics

Cytokinetics hit a setback in the development of its lead cancer candidate as the South San Francisco-based biotech said a midstage clinical trial missed the primary goal.

Eye On Stocks For Friday, March 31, 2006Eye On Stocks For Friday, March 31 2006

Cytokinetics is developing the drug with British pharmaceutical giant GlaxoSmithKline; results of a separate Phase II trial are pending.

Eye On Stocks For Friday, March 31, 2006Eye On Stocks For Friday, March 31 2006

Cytokinetics is also conducting research and non-clinical development of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions associated with excessive smooth muscle contraction, such as bronchoconstriction associated with asthma and chronic obstructive pulmonary disorder COPD.

unknown title 2011

Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements.

unknown title 2011

Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction.

unknown title 2011

In addition, prior Cytokinetics' research generated three anti-cancer drug candidates that have progressed into clinical development: ispinesib, SB-743921 and GSK-923295.

unknown title 2011

Examples of such statements include, but are not limited to, statements relating to Cytokinetics' research and development activities, including the significance and utility of pre-clinical research results, and the potential for smooth muscle myosin inhibition as a therapeutic approach for treatment of hypertension; and the properties and potential benefits of Cytokinetics' compounds.

unknown title 2011

Additional information about Cytokinetics can be obtained at

unknown title 2011

For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

unknown title 2011

All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton.

unknown title 2011